IMMNOV Immunovia AB (publ)
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Immunovia (STO: IMMNOV)
›
Immunovia (STO: IMMNOV) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 0.0501 SEK on 19 November 2026, down 83.3% over 52 weeks. Its 52-week range is 0.0300 SEK to 0.3200 SEK: the price is 84.3% below the high and 67.0% above the low.
Its market capitalisation is 50.78M SEK.
Immunovia reports return on equity of -225.3% and revenue up 734.7% year over year.
It holds more cash than debt, a net cash position of 16.69M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.